Pembrolizumab/Vibostolimab Co-Formulation + Pembrolizumab + Lenvatinib + 5-Fluorouracil + Cisplatin + Paclitaxel + Gemcitabine + Carboplatin + Docetaxel + Bevacizumab + Capecitabine + Oxaliplatin
Phase 2CompletedDevelopment Stage
Uterine Cervical Neoplasms
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Sep 16, 2021 → Aug 5, 2025
About Pembrolizumab/Vibostolimab Co-Formulation + Pembrolizumab + Lenvatinib + 5-Fluorouracil + Cisplatin + Paclitaxel + Gemcitabine + Carboplatin + Docetaxel + Bevacizumab + Capecitabine + Oxaliplatin
Pembrolizumab/Vibostolimab Co-Formulation + Pembrolizumab + Lenvatinib + 5-Fluorouracil + Cisplatin + Paclitaxel + Gemcitabine + Carboplatin + Docetaxel + Bevacizumab + Capecitabine + Oxaliplatin is a phase 2 stage product being developed by Merck for Uterine Cervical Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT05007106. Target conditions include Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05007106 | Phase 2 | Completed |
Competing Products
20 competing products in Uterine Cervical Neoplasms